Document is current
Any future updates will be listed below
-
Authors
ten Kate, Mara http://orcid.org/0000-0002-8290-8543
Ingala, Silvia
Schwarz, Adam J.
Fox, Nick C.
Chételat, Gaël
van Berckel, Bart N. M.
Ewers, Michael
Foley, Christopher
Gispert, Juan Domingo
Hill, Derek
Irizarry, Michael C.
Lammertsma, Adriaan A.
Molinuevo, José Luis
Ritchie, Craig
Scheltens, Philip
Schmidt, Mark E.
Visser, Pieter Jelle
Waldman, Adam
Wardlaw, Joanna
Haller, Sven
Barkhof, Frederik
-
Funding
Funding for this research was provided by:
EU/EFPIA Innovative Medicines Initiatives (EPAD 115736, AMYPAD 115952, EMIF 115372)
- License Information
-
More Information
Article History
Received: 9 July 2018
Accepted: 10 October 2018
First Online: 30 October 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: AJS is a full-time employee of Takeda Pharmaceuticals. MCI is a stock-holding employee of Eli Lilly and Company. Florbetapir F18 is owned and marketed by Avid/Lilly. Flortaucipir (18F-AV-1451) is an investigational agent under development by Avid/Lilly. DH is a full-time employee and stockholder of IXICO plc. ME is a full-time employee of Janssen Pharmaceutica. CF is a full-time employee of GE Healthcare. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
